Phase IV, Randomized, Open Label, Crossover, Intervention Trial to Investigate the Effect of the Switch of Lopinavir/Ritonavir to Raltegravir on Endothelial Function, Chronic Inflammation, Immune Activation and HIV Replication <50 Copies/ml.

Trial Profile

Phase IV, Randomized, Open Label, Crossover, Intervention Trial to Investigate the Effect of the Switch of Lopinavir/Ritonavir to Raltegravir on Endothelial Function, Chronic Inflammation, Immune Activation and HIV Replication <50 Copies/ml.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Raltegravir (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Acronyms RASSTER
  • Most Recent Events

    • 17 Dec 2013 Planned end date changed from 1 May 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 19 Oct 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2011-003298-26).
    • 06 Feb 2012 Actual initiation date (1 Jan 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top